A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer

Inclusion Criteria (abbreviated):

1. Documented adenocarcinoma of the pancreas

2. Stable metastatic pancreatic cancer after 8-12 doses of FOLFIRINOX

3. ECOG performance status of 0 or 1

4. Life expectancy greater than 3 months

5. Adequate organ and marrow function defined by study-specified laboratory tests.

6. Must use acceptable form of birth control while on study

7. Oxygen saturation on room air >92%

Exclusion Criteria (abbreviated):

1. Surgery within 4 weeks of dosing investigational agent (some exceptions for minor
procedures)

2. Off FOLFIRINOX treatment for more than 70 days prior to treatment on study

3. Prior chemotherapy for metastatic pancreatic cancer (other than FOLFIRINOX or adjuvant
therapy).

4. History of prior treatment with ipilimumab, anti-PD1 antibody, CD137 agonist, or
anti-CD40 antibody

5. Received any non-oncology live vaccine therapy up to one month prior to or after any
dose of ipilimumab/vaccine

6. Receiving any other investigational agents

7. Any of the following concomitant therapy: IL-2, interferon, immunosuppressive agents,
or chronic use of systemic corticosteroids

8. History of symptomatic autoimmune disease or immune impairment. Thyroid disease is
allowed.

9. Known brain metastasis

10. Radiographic ascites that is apparent on physical exam or requiring intervention in
the 2 months prior to enrollment

11. Uncontrolled intercurrent illness

12. Known or suspected hypersensitivity to GM-CSF

13. Chronic HIV, Hepatitis B or Hepatitis C

14. Pregnant or breastfeeding women